Table 3

Sociodemographic and clinical characteristics associated with second-line drug resistance among the studied M. tuberculosis isolates

CharacteristicNo. and proportion of isolates with resistance to:
Second-line drugsFirst- and second-line drugsPre-XDR-TB/XDR-TB
TotalNo. (%)OR (95% CI)aTotalNo. (%)OR (95% CI)aTotalNo. (%)OR (95% CI)a
Age1.01 (1.001–1.024)b1.03 (1.007–1.043)b1.02 (1.010–1.059)b
Sex
    Female11331 (27.4)1136 (5.3)11134 (3.5)1
    Male26783 (31.1)1.082 (0.665–1.761)26718 (6.7)1.29 (0.474–4.093)26713 (4.9)1.39 (0.418–5.999)
Anti-TB treatment history
    New32193 (29.0)32118 (5.6)132112 (3.7)1
    Previously treated5921 (35.6)1.44 (0.626–3.090)596 (10.2)2.33 (1.058–5.145)b595 (8.4)2.38 (0.630–7.616)
Cavity
    No25771 (27.6)125716 (6.2)125711 (4.3)1
    Yes12343 (35.0)1.131 (0.893–1.431)1238 (6.5)1.04 (0.377 −2.687)1236 (4.9)1.15 (0.340–3.480)
Previous uses of second-line drugc
    No26169 (26.4)134114 (4.1)134310 (2.9)1
    Yes11945 (37.8)1.60 (1.076–2.920)b3910 (25.6)8.05 (2.898–21.35)b377 (18.9)7.04 (2.129–21.49)b
  • a OR and 95% CI were calculated by comparing the drug-resistant rates between subjects with different sociodemographic and clinical features in the binary logistic regression model.

  • b P < 0.05.

  • c The association between previous uses of second-line drugs and drug resistance was analyzed by comparing the groups with previous use of the specific drug combinations (any second-line drugs, first- and second-line drugs, INH and RIF and any second-line drug) and that without use of the drug combinations.